The year chemotherapy finally gets some respect!
Crossref DOI link: https://doi.org/10.1038/nrurol.2014.362
Published Online: 2015-01-20
Published Print: 2015-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Saad, Fred
Text and Data Mining valid from 2015-01-20
Article History
First Online: 20 January 2015
Competing interests
: The author declares that he acts as a consultant and has received research funding from Abbvie, Amgen, Astellas, Janssen, Millennium, and Sanofi.